anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a traditional Chinese medicine composition for treating gastric ulcer, wherein Fructus Polygoni Orientalis and cuttlebone are used as a monarch drug for replenishing qi to invigorate spleen, clearing away heat and promoting dieresis, and dispersing blood stasis and relieving pain; and costustoot, radix angelicae, rhizoma atractylodis macrocephalae and cortex moutan are used as a ministerial drug for enhancing effects. Meanwhile, the costustoot further enables qi of tri-jiao to be ventilated, so as to recover the function of middle burner spleen and stomach lowering; the spleen prefers moisture to dryness and the rhizoma atractylodis macrocephalae can eliminate dampness and realize diuresis, so as to further enhance spleen and stomach functions, and keep healthy and do not be evil; and the function of removing blood stasis and producing new blood of the radix angelicae and the cortex moutan are adopted. Rhizoma bletillae and roasted concha arcae are used as adjuvant drugs to enhance hyperacidity relieving and skin generating functions. When the spleen and the stomach are healthy, qi is promoted and the blood stasis is removed and wetting heat is removed; and all the medicines are combined so as to replenish qi to invigorate the spleen, clear away heat and promote diuresis, remove blood stasis and relieve pain, and relieve hyperacidity and generate skin. The clinical utilization shows that the traditional Chinese medicine composition has the reliable curative effect on treating the gastric ulcer and has no untoward effects; and the traditional Chinese medicine composition can be accepted by vast gastric ulcer patients and is worthy of being popularized. The total effective rate is 90.5% and the traditional Chinese medicine composition is an effective drug for treating the gastric ulcer.
BACKGROUND: Dural arteriovenous fistulae (dAVF) are relatively infrequently encountered, and status epilepticus (SE) and lateralised periodic discharges (LPDs) on electroencephalography (EEG) have only rarely been associated with these arteriovenous malformations.
METHODS: We present a patient with recurrent presentations with focal SE, aphasia and other focal deficits of cortical function and ictal and peri-ictal LPDs on serial EEG, who was shown to have a left hemispheric dAVF associated with left transverse and sigmoid sinus thrombosis. Seizures proved refractory to four anti-seizure medications but became more amenable to control after successful embolisation of the dAVF, with subsequent resolution of the focal cortical deficits. We discuss the co-occurrence of SE and LPDs with dAVF and review previously reported cases with this rare association.
CONCLUSIONS: Our report supports a causative relationship between dAVF and focal SE, manifesting as ictal LPDs on EEG, and highlights the importance of active dAVF management in achieving seizure control. The relatively good patient outcome contrasts to the few similar case reports. Whilst rare, it is important to consider dAVF as a potentially treatable condition underlying new-onset seizures, including SE.
The present invention relates generally to systems and methods for treating cancer using immunogenic cell death, such as lysosome-induced immunogenic cell death. The present invention includes at least three aspects that may be used separately or together. The first aspect relates to the therapeutic preparation of a tumor, for example, by disabling and reducing antioxidants, as well as providing n-3 to n-6 and other unsaturated fatty acids, and/or treating a subject with statins. A second aspect relates to the restoration of p53 function through genetic manipulation including CRISPR technology. A third aspect relates to the construction of an antibody-enzyme complex, wherein the antibody recognizes the tumor and the enzyme is an oxidase. The complex can be administered to a subject. The substrate for the enzyme may also be administered to the subject. These and/or other aspects may be used alone or together and may be used to treat and/or cure cancer. In certain cases, lysosomes can be targeted to induce cell death in, for example, cancer cells.
EPM1 is the most common form of Progressive Myoclonus Epilepsy characterized by late-childhood onset, ever-worsening and disabling myoclonus, seizures, ataxia, psychiatric disease, and shortened lifespan. EPM1 is caused by expansions of a dodecamer repeat sequence in the promoter of CSTB (cystatin B), which dramatically reduces, but does not eliminate, gene expression. The relatively late onset and consistent presence of a minimal amount of protein product makes EPM1 a favorable target for gene replacement therapy. If treated early, these children's normally developed brains could be rescued from the neurodegeneration that otherwise follows, and their cross-reactive immunological material (CRIM) positive status greatly reduces transgene related toxicity. We performed a proof-of-concept CSTB gene replacement study in Cstb knockout mice by introducing full-length human CSTB driven by the CBh promoter packaged in AAV9 and administered at postnatal days 21 and 60. Mice were sacrificed at 2 or 9 months of age, respectively. We observed significant improvements in expression levels of neuroinflammatory pathway genes and cerebellar granule cell layer apoptosis, as well as amelioration of motor impairment. The data suggest that gene replacement is a promising therapeutic modality for EPM1 and could spare affected children and families the ravages of this otherwise severe neurodegenerative disease.
Patients have baseline data collected two weeks pre-intervention by assessing patient symptomatology using the dizziness handicap inventory, activities specific balance confidence questionnaires and a simulator sickness questionnaire remotely. Next, an interview will be conducted to collect information including age, sex, ethnicity, physical activity level and VR experience. Lastly, VR headset will be mailed to patients home address. A date for VR device tutorial will be discussed during this interview. Next patients will undergo 4 or 8 weeks of vestibular rehabilitation if diagnosed with unilateral or bilateral vestibular hypofunction respectively. This involves weekly 40-45 minute in-person sessions with a physiotherapist and three 20 minute sessions a day of at-home independent exercises. In addition, they will undergo an at home VR vestibular rehabilitation protocol that involves playing a video game projected on an android or apple device in a VR headset for 20 minutes daily.
In all participating Emergency Departments, patients with highly suspected or confirmed COVID-19 are evaluated for potential inclusion. Clinical, biological, and imaging data that may be involved in decision-making about hospitalization, including all criteria of the revised HOME-CoV score, are collected. The revised HOME-CoV score is calculated. Patients with a score \<2 qualify for home treatment. They qualify otherwise for hospitalization. For patients with a score \> 4, hospitalization in a unit allowing monitoring of vital parameters is recommended. The qualification for home treatment or for hospitalization can be overruled by the physician-in-charge in case of major medical or social reasons. A justification explaining the cause of overruling is required.

A phone-call follow-up is performed on Day 7 and the patients' clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Health Organization (WHO-OSCI) is collected.
BACKGROUND: Buprenorphine may be safer and better-tolerated than full mu opioid receptor (MOR) agonists. Whether it effectively controls cancer-related pain is unclear. A prior review (Cochrane 2015) did not support prioritizing buprenorphine over full MOR agonists for cancer-associated pain.
PURPOSE/HYPOTHESIS: We conducted an updated systematic review of buprenorphine's effect on cancer- related pain including both new studies and additional study designs. Procedures/data/observations: We searched Cochrane, OVID Medline, EMBASE, EBSCO and Web of Science for studies published in any language up to May 2023 for studies that examined buprenorphine's impact upon pain severity/intensity in patients with active cancer. Risk of bias and study quality were assessed using the Cochrane Collaboration tool for randomized controlled trials (RCTs), and the Newcastle-Ottawa Scale for cohort and casecontrol studies. Data were synthesized using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria.
CONCLUSIONS/APPLICATIONS: 2322 publications were identified and 42 studies were included (14 RCTs, 10 pre-post uncontrolled, 5 cohort, and 2 case-control studies). All had moderate-high risk of bias. One RCT showed buprenorphine was superior to placebo. 11 RCTs (12 papers) showed buprenorphine was as effective as full MOR agonists for cancer pain. 10-30 percent of cancer patients trialing buprenorphine did not achieve adequate response.
BACKGROUND: This study aims to assess the long-term outcomes of a modified pneumatic reduction protocol for intussusception at the Vietnam National Hospital of Pediatrics, an institution with a significant patient load in a lower-middle-income country.
PATIENTS AND METHODS: A single center, retrospective cohort observational study was conducted to examine patients who underwent modified fluoroscopic-guided air-enema reduction (FGAR) for intussusception from January 2016 to December 2017. Data on patient demographics, complication rates, and the incidence of long-term recurrence was collected.
RESULTS: Between January 2016 and December 2017, a total of 3562 patients underwent modified FGAR at our institution, including 2313 males (64.9%) and 1249 females (35.1%). The median age was 19 months (range: 1-170), and the median FGAR procedure duration was 4 min (range: 2-24). The median hospital stay was 1 day (range: 1-31). Successful reduction was achieved in 98.7% of cases, with 43 unsuccessful cases and 4 cases of perforated bowel requiring surgery. Twenty patients, presenting with severe symptoms due to delayed treatment seeking, were admitted to the pediatric intensive care unit (ICU) post-FGAR. No mortality or severe morbidity was reported. Over a median 6-year follow-up, intussusception recurred in 198 patients, accounting for 5.6% of the cohort, with 97% of recurrences occurring within the first year post-reduction. Infants and children under 12 months of age had the highest complication rates, including failed FGAR, complicated intussusception, ICU admission, or recurrence, compared to other age groups, and this difference was statistically significant (p < 0.05).
CONCLUSION: The modified FGAR protocol has been demonstrated to be safe and feasible, with a very high success rate, low complication rate, and low recurrence rate. Although further comparative studies are needed to confirm its reproducibility, it should be considered a promising approach for children in low-to middle-income countries.
LEVEL OF EVIDENCE: Level III.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to dermatology and maxillofacial surgery, and can be used in the treatment of patients with abscessed boils of the upper and lower areas of the face. Method of treatment includes treating the site of inflammation with an antiseptic solution, removing the purulo-necrotic mass with a syringe and applying a dressing with an ointment. Used a disposable sterile syringe "Luer", with a needle from the kit previously make a puncture in the center of the infiltrate. Then the syringe is cut off the end part of the cylinder along the first mark of the graduated scale and attached to it a perforated silicone gasket, whose diameter is 2 mm larger than the diameter of the syringe. Use a syringe as a vacuum extractor to completely absorb the purulo-necrotic stem, purulent contents of the pustule, and obtain a single drop of blood. Resulting cavity is then washed with a 3 % hydrogen peroxide solution and an aqueous solution of 0.05 % chlorhexidine. On the inflammatory infiltrate area, 70 % alcohol compress is applied for 15–20 minutes every 2–3 hours for 2 days. Overnight, put a dressing with saline solution for 3 days. From 4 to 7 days impose ointment dressings with "Levomekol" with an interval of 1 day. Conducted also a standard course of antibiotic therapy, indicated for pyoinflammatory diseases of the maxillofacial area.EFFECT: method of treatment is simple and convenient to use, it allows the most effective treatment of abscessed boils with minimization of the operating injury of the soft tissues of the upper and lower areas of the face.1 cl, 2 dwg
PCT No. PCT/EP97/02504 Sec. 371 Date Nov. 12, 1998 Sec. 102(e) Date Nov. 12, 1998 PCT Filed May 12, 1997 PCT Pub. No. WO97/44039 PCT Pub. Date Nov. 27, 1997The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising: (1) as an active ingredient a therapeutically effective amount of a 9-hydroxyrisperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof and (2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein; and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.
502,410. Cosmetics. DEHN, F. B. (Factor & Co., M.) Sept. 11, 1937, No. 24820. Drawings to Specification. [Class 81 (i)] A cosmetic preparation, such as a powder or foundation cream, adapted for use on individuals to be photographed or panchromatic type emulsions comprises white and coloured pigments so blended that the preparation has a high reflection coefficient to light of wavelengths of about 6200 to 6500 A and lower reflection coefficients to light of shorter wavelengths, the reflection coefficient to light within the range 4000 to 4500 A being 45 per cent to 75 per cent of the reflection coefficient to light within the range 6200 to 6500 A. The reflection coefficients of the preparations are ascertained by spectrographio methods. The pigments employed should consist to the extent of 50 per cent or over, of white pigments such as titanium and zinc oxides. The coloured pigments comprise materials such as ivoryblack, blue and red lakes, ochre, and substances used in the art as sienna and umber substitutes. Mineral oils, vegetable oils, and mixtures thereof with or without alcohols, wetting-agents, &c. are used as vehicles.
This is a randomized (study medication assigned to participants by chance), double-blind (neither the investigator nor the participants know what treatment the participant is receiving), placebo-controlled (an inactive comparator treatment that has no study drug in it), single center study in healthy male participants and female participants of non-childbearing potential (surgically sterile or post menopausal), aged 18 to 58 years inclusive. This study will consist of two parts; a Single Ascending Dose (SAD) part and a Multiple Ascending Dose (MAD) part. The SAD will consist of 6 escalating dose cohorts. Participants in each cohort will be randomized to receive a single oral administration of JNJ-55375515 or placebo after an overnight fast. The planned doses of JNJ-55375515 range from 0.75 to 100 milligrams (mg). Participants in an additional cohort will be dosed in the fed state to determine the effects of food on the safety, tolerability and pharmacokinetics of JNJ-55375515. An additional optional cohort may be evaluated to further explore the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-55375515, with the maximal dose not exceeding 200 mg. The study duration for participants in the SAD part of the study will be approximately 2 to 5.5 weeks, including eligibility Screening. The MAD will consist of 3 cohorts of 9 participants. Participants will receive once daily oral doses of JNJ-55375515 or placebo for 10 consecutive days. The study duration for participants in the MAD part of this study will be approximately 3 to 7 weeks including the eligibility Screening. The Safety of Participants will be monitored throughout the study.
Patients randomized to the Standard Therapy arm will not undergo genotyping at the time of percutaneous coronary intervention. All patients will receive clopidogrel 75 mg daily for 1 week. At the end of the 1 week period, their CYP2C19\*2 carrier status will be verified.
Cholesterol crystal embolism (CCE) implies immunothrombosis, tissue necrosis, and organ failure but no specific treatments are available. As CCE involves complement activation, we speculated that inhibitors of the C5a/C5aR axis would be sufficient to attenuate the consequences of CCE like that with systemic vasculitis. Cholesterol microcrystal injection into the kidney artery of wild-type mice initiated intra-kidney immunothrombosis within a few hours followed by a sudden drop of glomerular filtration rate and ischemic kidney necrosis after 24 hours. Genetic deficiency of either C3 or C5aR prevented immunothrombosis, glomerular filtration rate drop, and ischemic necrosis at 24 hours as did preemptive treatment with inhibitors of either C5a or C5aR. Delayed C5a blockade after crystal injection still resolved crystal clots and prevented all consequences. Thus, selective blockade of C5a or C5aR is sufficient to attenuate the consequences of established CCE and prospective inhibition in high-risk patients may be clinically feasible and safe.
AIM: Laparoscopic hysteropexy is a complicated procedure that requires specialized surgical skills, including precise dissection and suturing. The aim is to describe the technical considerations for performing a new, feasible, and minimally invasive technique to correct apical and concurrent apical and anterior vaginal wall defects.
METHOD: A retrospective analysis was conducted on 70 consecutive women who underwent surgery for stage ≥3 uterovaginal prolapse. As a part of the technique, an anterior 2-cm long transverse incision was made at the anterior cervicovaginal junction, and the bladder was dissected through blunt and sharp dissection to the level of the isthmus. A posterior colpotomy was performed. A polypropylene tape was inserted into the cervical connective tissue, and the free arms of the tape were inserted into the peritoneum via the posterior colpotomy. Two arms of the tape were passed from the tunnel parallel and medial to a right sacrouterine fold, then fixed to the anterior longitudinal ligament via the laparoscopic route.
RESULTS: The tape can be inserted into the cervix in a median of 15 min, and the laparoscopy procedure can be completed in 24 min. No mesh erosion or long-term complications occurred. At a 1-year control, there were no cases of recurrence.
CONCLUSIONS: This novel cervico-sacrocolpopexy technique is a feasible and safe, minimally invasive way to correct apical or multicompartment defects, with a short operation time and an anatomical result that mimics the normal sacrouterine ligament.
Patients will receive two infusions simultaneously, at each study visit, one of Zoledronic acid and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
Inspiratory Muscle Training (IMT) should be considered an additional intervention in the pulmonary rehabilitation program for patients with advanced lung disease. The aim of this study is to evaluate, the effects of inspiratory muscle training program in inspiratory muscle function, functional capacity, quality of life, lung function, breathing pattern and chest wall motion in patients with advanced lung disease. It is a quasi-experimental study with longitudinal design. Patients with advanced lung disease from the advanced lung disease and pre lung transplantation ambulatory performed home-based high intensity interval IMT for 8 weeks (two sessions per day, daily). In each session patients executed two times 30 breaths with one-minute rest between them. Resistance was set to the highest tolerable according to scores pointed by the patient on the Borg score (between 4 and 6) aiming 50% of actual pimax or higher. An experienced physiotherapist was responsible for weekly adjustments on the resistance of training as well as new assessment of maximal inspiratory pressure. Patients were evaluated before the inspiratory muscle training, after 8 weeks of training and at follow-up which was performed 3 months after the end of the intervention. Patients were evaluated by the same experienced researcher in all three moments of the study. Evaluations were performed in the Laboratory of research and evaluation of cardiorespiratory performance of Federal University of Minas Gerais.
The invention relates to fructus cannabis healthcare tea for wind-warm syndromes. The healthcare tea is prepared by separately smashing 21 g of fructus cannabis, 15 g of forsythia fruit, 15 g of balloon flower root, 18 g of mint, 21 g of honeysuckle flower, 21 g of arnebia root and 25 g of green tea into powder with particle size being 50 meshes, mixing the powder uniformly, adding into a closed container, feeding water vapor for 1-3 h, with the pressure being controlled at 530-600 KP and the temperature being controlled at 146-160 DEG C, drying the powder by utilization of a low-temperature vacuum drying method, filling into a filter bag and sealing. The raw materials of the healthcare tea are clean and have less impurity. Brewing and drinking effects are good. The healthcare tea has functions of clearing away heat and toxic materials, dispelling wind and relieving exterior syndrome. Frequent brewing and drinking of the healthcare tea can clear away heat and toxic materials, dispel wind and relieve exterior syndrome, and relieve discomfort caused by wind-warm syndromes for people.